6 ADVERSE REACTIONS
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
- •
- Splenic Rupture [see Warnings and Precautions (5.1)]
- •
- Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2)]
- •
- Serious Allergic Reactions [see Warnings and Precautions (5.3)]
- •
- Sickle Cell Disorders [see Warnings and Precautions (5.4)]
- •
- Glomerulonephritis [see Warnings and Precautions (5.5)]
- •
- Alveolar Hemorrhage and Hemoptysis [see Warnings and Precautions (5.6)]
- •
- Capillary Leak Syndrome [see Warnings and Precautions (5.7)]
- •
- Myelodysplastic Syndrome [see Warnings and Precautions (5.8)]
- •
- Acute Myeloid Leukemia [see Warnings and Precautions (5.8)]
- •
- Thrombocytopenia [see Warnings and Precautions (5.9)]
- •
- Leukocytosis [see Warnings and Precautions (5.10)]
- •
- Cutaneous Vasculitis [see Warnings and Precautions (5.11)]
- •
- Aortitis [see Warnings and Precautions (5.15)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions in Patients with Cancer Receiving Myelosuppressive Chemotherapy
The following adverse reaction data in Table 2 are from three randomized, placebo-controlled studies in patients with:
- •
- small cell lung cancer receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide (Study 1)
- •
- small cell lung cancer receiving ifosfamide, doxorubicin‚ and etoposide (Study 2), and
- •
- non-Hodgkin's lymphoma (NHL) receiving doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, and methotrexate ("ACVBP") or mitoxantrone, ifosfamide, mitoguazone, teniposide, methotrexate, folinic acid, methylprednisolone, and methotrexate ("VIM3") (Study 3).
A total of 451 patients were randomized to receive subcutaneous filgrastim 230 mcg/m2 (Study 1), 240 mcg/m2 (Study 2) or 4 or 5 mcg/kg/day (Study 3) (n = 294) or placebo (n = 157). The patients in these studies were median age 61 (range 29 to 78) years and 64% were male. The ethnicity was 95% Caucasian, 4% African American, and 1% Asian.
System Organ Class Preferred Term | Filgrastim (N = 294) | Placebo (N = 157) |
---|---|---|
| ||
Blood and lymphatic system disorders | ||
Thrombocytopenia | 38% | 29% |
Gastrointestinal disorders | ||
Nausea | 43% | 32% |
General disorders and administration site conditions | ||
Pyrexia | 48% | 29% |
Chest pain | 13% | 6% |
Pain | 12% | 6% |
Fatigue | 20% | 10% |
Musculoskeletal and connective tissue disorders | ||
Back pain | 15% | 8% |
Arthralgia | 9% | 2% |
Bone pain | 11% | 6% |
Pain in extremity* | 7% | 3% |
Nervous system disorders | ||
Dizziness | 14% | 3% |
Respiratory, thoracic and mediastinal disorders | ||
Cough | 14% | 8% |
Dyspnea | 13% | 8% |
Skin and subcutaneous tissue disorders | ||
Rash | 14% | 5% |
Investigations | ||
Blood lactate dehydrogenase increased | 6% | 1% |
Blood alkaline phosphatase increased | 6% | 1% |
Adverse events with ≥ 5% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy delivered included anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, edema peripheral, hemoglobin decreased, decreased appetite, oropharyngeal pain, and alopecia.
Adverse Reactions in Patients with Acute Myeloid Leukemia
Adverse reaction data below are from a randomized, double-blind, placebo-controlled study in patients with AML (Study 4) who received an induction chemotherapy regimen of intravenous daunorubicin days 1, 2, and 3; cytosine arabinoside days 1 to 7; and etoposide days 1 to 5 and up to 3 additional courses of therapy (induction 2, and consolidation 1, 2) of intravenous daunorubicin, cytosine arabinoside, and etoposide. The safety population included 518 patients randomized to receive either 5 mcg/kg/day filgrastim (n = 257) or placebo (n = 261). The median age was 54 (range 16 to 89) years and 54% were male.
Adverse reactions with ≥ 2% higher incidence in filgrastim patients compared to placebo included epistaxis, back pain, pain in extremity, erythema, and rash maculo-papular.
Adverse events with ≥ 2% higher incidence in filgrastim patients compared to placebo and associated with the sequelae of the underlying malignancy or cytotoxic chemotherapy included diarrhea, constipation, and transfusion reaction.
Adverse Reactions in Patients with Cancer Undergoing Bone Marrow Transplantation
The following adverse reaction data are from one randomized, no treatment-controlled study in patients with acute lymphoblastic leukemia or lymphoblastic lymphoma receiving high-dose chemotherapy (cyclophosphamide or cytarabine, and melphalan) and total body irradiation (Study 5) and one randomized, no treatment-controlled study in patients with Hodgkin's disease (HD) and NHL undergoing high-dose chemotherapy and autologous bone marrow transplantation (Study 6). Patients receiving autologous bone marrow transplantation only were included in the analysis. A total of 100 patients received either 30 mcg/kg/day as a 4-hour infusion (Study 5) or 10 mcg/kg/day or 30 mcg/kg/day as a 24-hour infusion (Study 6) filgrastim (n = 72), no treatment control or placebo (n = 28). The median age was 30 (range 15 to 57) years, 57% were male.
Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included rash and hypersensitivity.
Adverse reactions in patients receiving intensive chemotherapy followed by autologous BMT with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included thrombocytopenia, anemia, hypertension, sepsis, bronchitis, and insomnia.
Adverse Reactions in Patients with Cancer Undergoing Autologous Peripheral Blood Progenitor Cell Collection
The adverse reaction data in Table 3 are from a series of 7 trials in patients with cancer undergoing mobilization of autologous peripheral blood progenitor cells for collection by leukapheresis. Patients (n = 166) in all these trials underwent a similar mobilization/collection regimen: filgrastim was administered for 6 to 8 days‚ in most cases the apheresis procedure occurred on days 5‚ 6, and 7. The dosage of filgrastim ranged between 5 to 30 mcg/kg/day and was administered subcutaneously by injection or continuous infusion. The median age was 39 (range 15 to 67) years, and 48% were male.
System Organ Class Preferred Term | Mobilization Phase (N = 166) |
---|---|
Musculoskeletal and connective tissue disorders | |
Bone pain | 30% |
General disorders and administration site conditions | |
Pyrexia | 16% |
Investigations | |
Blood alkaline phosphatase increased | 11% |
Nervous system disorders | |
Headache | 10% |
Adverse Reactions in Patients with Severe Chronic Neutropenia
The following adverse reaction data were identified in a randomized, controlled study in patients with SCN receiving filgrastim (Study 7). 123 patients were randomized to a 4-month observation period followed by subcutaneous filgrastim treatment or immediate subcutaneous filgrastim treatment. The median age was 12 years (range 7 months to 76 years) and 46% were male. The dosage of filgrastim was determined by the category of neutropenia. Initial dosage of filgrastim:
- •
- Idiopathic neutropenia: 3.6 mcg/kg/day
- •
- Cyclic neutropenia: 6 mcg/kg/day
- •
- Congenital neutropenia: 6 mcg/kg/day divided 2 times per day
The dosage was increased incrementally to 12 mcg/kg/day divided 2 times per day if there was no response.
Adverse reactions with ≥ 5% higher incidence in filgrastim patients compared to patients receiving no filgrastim included arthralgia, bone pain, back pain, muscle spasms, musculoskeletal pain, pain in extremity, splenomegaly, anemia, upper respiratory tract infection, and urinary tract infection (upper respiratory tract infection and urinary tract infection were higher in the filgrastim arm, total infection related events were lower in filgrastim-treated patients), epistaxis, chest pain, diarrhea, hypoesthesia, and alopecia.
6.2 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of filgrastim products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- •
- splenic rupture and splenomegaly (enlarged spleen) [see Warnings and Precautions (5.1)]
- •
- acute respiratory distress syndrome [see Warnings and Precautions (5.2)]
- •
- anaphylaxis [see Warnings and Precautions (5.3)]
- •
- sickle cell disorders [see Warnings and Precautions (5.4)]
- •
- glomerulonephritis [see Warnings and Precautions (5.5)]
- •
- alveolar hemorrhage and hemoptysis [see Warnings and Precautions (5.6)]
- •
- capillary leak syndrome [see Warnings and Precautions (5.7)]
- •
- leukocytosis [see Warnings and Precautions (5.10)]
- •
- cutaneous vasculitis [see Warnings and Precautions (5.11)]
- •
- Sweet's syndrome (acute febrile neutrophilic dermatosis)
- •
- decreased bone density and osteoporosis in pediatric patients receiving chronic treatment with filgrastim products.
- •
- myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast and lung cancer receiving chemotherapy and/or radiotherapy [see Warnings and Precautions (5.8)]
- •
- aortitis [see Warnings and Precautions (5.15)]
- •
- extramedullary hematopoiesis